• 071CINV Banner 1150x300

Overview

STATEMENT OF NEED

The introduction of effective antiemetic regimens in recent years has led many clinicians to assume that CINV is no longer a major problem. However, nausea and vomiting are frequent complications of cancer treatment, occurring in up to 80% of patients receiving chemotherapy. Furthermore, wide gaps exist between patient and provider perceptions of nausea and vomiting. Clinicians often consider nausea and vomiting “minor” complications and regard these symptoms as inconveniences rather than serious medical problems. On the contrary, uncontrolled CINV is reported by patients to significantly impair their quality of life and reduce daily functioning. Uncontrolled CINV may also lead to severe clinical conditions, including electrolyte imbalance, dehydration, and malnutrition, which may compromise a patient’s ability to respond to cancer therapy. Additionally, research has shown that uncontrolled CINV may be detrimental to survival. Moreover, the costs associated with uncontrolled CINV represent a significant economic burden to the health care system.

TARGET AUDIENCE

Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the management of chemotherapy-induced nausea and vomiting (CINV).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

  • Assess the risk for nausea and vomiting in cancer patients scheduled to receive chemotherapy
  • Identify chemotherapeutic agents with high and moderate emetic risk
  • Differentiate antiemetic regimens for acute, delayed, breakthrough, and refractory CINV
  • Apply strategies to promote patient self-report of symptoms for optimal CINV control

FACULTY

Rebecca Clark-SnowRebecca Clark-Snow, RN, BSN, OCN® (Chairperson)
Oncology Consultant

Una HopkinsUna T. Hopkins, DNP
Administrative Director
Dickstein Cancer Treatment Center at White Plains Hospital

REGISTRATION

There is no fee to participate in or claim CE credit for this activity.

Jointly Provided by

  PIM Logoi3 Health Logo

ACCREDITATION

The Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This educational activity for 1.0 contact hour is provided by the Postgraduate Institute for Medicine. Designated for .50 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

ACTIVITY DATES

December 22, 2017 – December 21, 2018

PREREQUISITES

No prerequisites are required for this activity.

ONCC RECERTIFICATION 

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

OCN®, CPHON®, CBCN®, AOCNP®, and AOCNS® renewal candidates: 1 ILNA point may be applied toward: 
Symptom Management ......................................................1 point      

BMTCN® renewal candidates: 1 ILNA point may be applied toward:
Post-Transplant Issues ........................................................1 point     

Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of CNE awarded from this course.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

Ms. Clark-Snow discloses that she has served on the speakers bureau for Merck.
Dr. Hopkins discloses that she has served as a consultant for Eisai.

Planners and Managers

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. i3 Health planners and managers have no relevant financial relationships to disclose.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must:

  1. Take the pretest
  2. Read the monograph
  3. Pass the posttest with a score of ≥80%
  4. Complete the activity evaluation
  5. Download or print their Certificate of Credit

UNAPPROVED USE DISCLOSURE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

COMMERCIAL SUPPORT

This activity is supported by an independent educational grant from Merck.

CONTACT INFORMATION

If you have technical queries about this activity or issues with your CE certificate, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.. For questions regarding the activity’s accreditation, please contact the accredited provider at This email address is being protected from spambots. You need JavaScript enabled to view it..

Start Activity